Sang­amo shares take a big hit as in­vestors re­act to set­back for pi­o­neer­ing gene-edit­ing tech

Sang­amo $SG­MO to­day re­leased the first snap­shots from two ear­ly-stage stud­ies look­ing at the ef­fect their first-gen­er­a­tion gene edit­ing tech­nol­o­gy has on two rare and lethal dis­eases — MPS I and II. And from it Sang­amo CEO Sandy Macrae has reached two ba­sic con­clu­sions:

“It’s work­ing and it’s not suf­fi­cient for a clin­i­cal ben­e­fit.”

That con­clu­sion — along with Sang­amo’s as­ser­tion that their zinc fin­ger nu­cle­ase ap­proach is safe — is dri­ving a switch-up in the clin­ic, where the biotech is pur­su­ing a his­toric at­tempt to en­gi­neer a break­through in gene-edit­ing hu­mans af­ter years of an­i­mal re­search.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER